What’s Vascular Biogenics Ltd. (VBLT) Downside After Reaching All-Time Low?

March 18, 2018 - By Henry Gaston

The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) reached all time low today, Mar, 18 and still has $2.14 target or 6.00 % below today’s $2.28 share price. This indicates more downside for the $67.62M company. This technical setup was reported by Barchart.com. If the $2.14 PT is reached, the company will be worth $4.06M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 4.21% or $0.1 during the last trading session, reaching $2.275. About 650,977 shares traded or 62.36% up from the average. Vascular Biogenics Ltd. (NASDAQ:VBLT) has risen 78.91% since March 18, 2017 and is uptrending. It has outperformed by 62.21% the S&P500.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Vascular Biogenics had 17 analyst reports since August 24, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $11 target in Tuesday, March 28 report. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Mkt Outperform” rating given on Monday, September 21 by JMP Securities. On Tuesday, October 3 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Neutral” rating by H.C. Wainwright given on Thursday, March 8. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. As per Thursday, March 8, the company rating was downgraded by JMP Securities. The rating was downgraded by Piper Jaffray to “Hold” on Thursday, March 8. The firm has “Neutral” rating by Chardan Capital Markets given on Friday, March 9. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Buy” rating given on Monday, September 21 by Chardan Capital Markets. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, June 28.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $67.62 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.